Prospective Multicenter Cohort Study of Clinical and Molecular Biomarkers in Colorectal Cancer
Prospective Cohort Study to Investigate Clinical Factors and Molecular Biomarkers Associated With Treatment Response and Disease Outcomes in Patients With Colorectal Cancer in Vorarlberg, Austria
This prospective, multicenter observational study aims to identify clinical and molecular biomarkers associated with treatment response, disease recurrence, progression, and survival in patients with colorectal cancer (CRC).
Approximately 200 adult patients undergoing surgical resection for CRC will be enrolled and followed for up to five years. Tumor tissue and blood samples will be collected for molecular analyses, and clinical data will be recorded longitudinally to investigate associations between biomarkers and disease outcomes.
All treatment decisions will follow standard clinical practice and will not be influenced by study participation.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Colorectal cancer is a heterogeneous disease characterized by substantial variability in tumor biology, treatment response, and clinical outcomes. The identification of reliable molecular biomarkers may improve risk stratification, facilitate the detection of disease recurrence, and support the development of personalized treatment strategies.
This prospective, multicenter observational cohort study aims to establish a longitudinal biobank of biological specimens linked to comprehensive clinical data from patients with colorectal cancer undergoing surgical treatment.
Biological specimens, including tumor tissue, adjacent non-malignant tissue, and peripheral blood, will be collected and stored for molecular and biochemical investigations. Serial blood sampling during follow-up will enable the investigation of longitudinal changes in circulating biomarkers and their potential association with disease progression, treatment response, and clinical outcomes.
Planned research activities include molecular characterization of tumor tissue, analysis of circulating tumor DNA (ctDNA), investigation of tumor-associated genetic alterations, gene expression profiling, and measurement of circulating biomarkers. Where feasible, patient-derived tumor cells may also be isolated and cultured for exploratory investigations.
Clinical information, including tumor characteristics, treatment modalities, and disease course, will be documented prospectively and linked to the collected biological specimens. This integrated approach will enable the investigation of associations between molecular characteristics, longitudinal biomarker dynamics, and clinical outcomes.
The study is intended to provide a comprehensive research resource for identifying and validating prognostic and predictive biomarkers in colorectal cancer. All diagnostic and therapeutic decisions will be made according to routine clinical practice and will not be influenced by study participation.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Thomas Winder, MD, PhD
- Número de teléfono: +43 5522 3032694
- Correo electrónico: Thomas.Winder@vlkh.at
Copia de seguridad de contactos de estudio
- Nombre: Axel Muendlein, PhD
- Número de teléfono: +43 5572 3726581
- Correo electrónico: axel.muendlein@vivit.at
Ubicaciones de estudio
-
-
Vorarlberg
-
Bregenz, Vorarlberg, Austria, 6900
- Reclutamiento
- Landeskrankenhaus Bregenz
-
Contacto:
- Claudius Falch, MD
-
Feldkirch, Vorarlberg, Austria, 6800
- Reclutamiento
- Landeskrankenhaus Feldkirch
-
Contacto:
- Jürgen Parzefall, MD
-
Contacto:
- Markus Weigl, MD
-
Hohenems, Vorarlberg, Austria, 6845
- Activo, no reclutando
- Landeskrankenhaus Hohenems
-
Rankweil, Vorarlberg, Austria, 6830
- Activo, no reclutando
- Landeskrankenhaus Rankweil
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
The study population consists of adult patients (aged 18 years or older) diagnosed with colorectal cancer who undergo surgical resection at participating hospitals in Vorarlberg, Austria. Patients will be consecutively recruited irrespective of tumor stage (UICC I-IV) or planned neoadjuvant or adjuvant treatment. All participants must provide written informed consent. Clinical data and biological samples will be collected prospectively, and patients will be followed for up to five years after surgery.
Descripción
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed colorectal carcinoma.
- Planned surgical resection of the primary colorectal tumor.
- Written informed consent to participate in the study.
Exclusion Criteria:
- Age <18 years.
- Pregnancy.
- Individuals held in custody by order of a court or public authority.
- Known current alcohol and/or illicit drug abuse that, in the investigator's judgment, may compromise participant safety and/or compliance.
- Inability to understand and sign the informed consent form.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Survival (OS)
Periodo de tiempo: Up to 5 years after surgical resection
|
Overall survival (OS) is defined as the time from surgical resection of colorectal cancer to death from any cause. Patients who are alive at the end of the follow-up period will be censored at the date they were last known to be alive. |
Up to 5 years after surgical resection
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Disease-Free Survival (DFS)
Periodo de tiempo: Up to 5 years after surgical resection
|
Disease-free survival (DFS) is defined as the time from achievement of a disease-free state following curative-intent treatment to the first documented recurrence of colorectal cancer or death from any cause, whichever occurs first. DFS will be assessed in patients with no evidence of residual disease following treatment, including patients with completely resected metastatic disease. Patients without an event will be censored at the date of their last available disease assessment. |
Up to 5 years after surgical resection
|
|
Progression-Free Survival (PFS)
Periodo de tiempo: Up to 5 years after surgical resection
|
Progression-free survival (PFS) is defined as the time from surgical resection to the first documented disease progression or death from any cause, whichever occurs first. PFS will be assessed in patients with residual or metastatic colorectal cancer following surgery. Patients without an event will be censored at the date of their last available disease assessment. |
Up to 5 years after surgical resection
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Thomas Winder, MD, PhD, Landeskrankenhaus Feldkirch
- Director de estudio: Axel Muendlein, PhD, Vorarlberg Institute for Vascular Investigation and Treatment
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- DK-24-05-2023
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
No formal plan for sharing individual participant data (IPD) with external researchers has been established. Any future data sharing will be subject to applicable data protection regulations, ethical requirements, and appropriate data-sharing agreements. Study results will be published in aggregated form.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .